Clin2
NCT07579884Possibly a fitNot yet recruiting

Safety and Efficacy of RP902 for Early Memory Loss

Mild Cognitive Impairment (MCI)

Part of Mental health clinical trials.

This trial tests a new medication called RP902 to see if it can safely help people with mild cognitive impairment—the early stage of memory and thinking problems that may lead to dementia. Researchers will measure how well it works and monitor for side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
360 people
Ages
50 years to 85 years
Study type
Interventional

Who can take part

  • You have mild cognitive impairment (early memory loss) diagnosed by a doctor, not caused by stroke or other diseases
  • Your memory and thinking score on standard tests falls within a specific mild range (MMSE ≥ 24, CDR-GS = 0.5)
  • You are not severely depressed (Hamilton Depression score ≤ 10)
  • You do not have active infections, serious heart/lung/digestive problems, or recent cancer
  • You have not taken part in another drug trial in the past 3 months
  • You are able to read and write at a junior high school level and complete cognitive tests

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07236190Recruiting· Phase 2
Using brain markers to test NPC-1 for Alzheimer's

This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.

Boston, Massachusetts
NCT07027072Recruiting· Phase 2
Testing KDS2010 for early Alzheimer's memory loss

This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.

Gwangju, Gwangju
NCT07489599Not yet recruiting· Phase 1
Study of a new drug for mild Alzheimer's disease

This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.

NCT07094516Recruiting· Phase 2
Testing VHB937 for early Alzheimer's disease

This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.

Phoenix, Arizona
NCT07781657Not yet recruiting· Phase 2
Testing an experimental drug for early Alzheimer's disease

This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.

NCT07234942Recruiting· Phase 1
Safety study of RO7812653 for early Alzheimer's disease

This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.

Toronto, Ontario

Hear when a new Mild Cognitive Impairment (MCI) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.